Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms COAST-W
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 03 Jun 2023 Post-hoc results (n=587) from COAST-V, COAST-X, COAST-W studies presented at the 24th Annual Congress of the European League Against Rheumatism.
  • 15 Feb 2023 Results(n=932: from the COAST program at 3 years, 1 year of the originating studies (COAST-V/-W/-X) and 2 years of COAST-Y) assessing safety and efficacy of ixekizumab in patients with axial spondyloarthritis published in The Journal of Rheumatology
  • 01 Feb 2023 Results assessing the test-retest reliability, construct validity, known groups discrimination, and responsiveness of the Assessment of the SpondyloArthritis international Society Health Index (ASAS HI) to evaluate functioning, disability, and health in patients with radiographic axial spondyloarthritis (r-axSpA) from (COAST-V, N = 341; COAST-W, N = 316) studies, published in The Journal of Rheumatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top